Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2019 Jun;8(3):1014-1015.
doi: 10.21037/tcr.2019.04.17.

Erratum to anti-GD2 CAR T cells could prove transformative for H3-K27M+ diffuse midline gliomas

Koichi Furukawa  1 , Yuhsuke Ohmi  2 , Keiko Furukawa  1
Affiliations
Published Erratum

Erratum to anti-GD2 CAR T cells could prove transformative for H3-K27M+ diffuse midline gliomas

Koichi Furukawa et al. Transl Cancer Res. 2019 Jun.

Abstract

[This corrects the article DOI: 10.21037/tcr.2018.08.21.].

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.04.17). The authors have no conflicts of interest to declare.

Figures

Figure 2
Figure 2
Anti-GD2 CAR T cells are promising approach to treat DIPG. Anti-GD2 CAR T cells could infiltrate into glioma tissues, and eliminate almost completely GD2-expressing cells after systemic injection (left). In contrast, anti-GD2 mAbs are hard to access glioma cells by crossing the blood brain barrier (right). This may be also the case in anti-immune check-point antibodies. DIPG, diffuse intrinsic pontine glioma.
See this image and copyright information in PMC

Erratum for

References

    1. Furukawa K, Ohmi Y, Furukawa K. Anti-GD2 CAR T cells could prove transformative for H3-K27M+ diffuse midline gliomas. Transl Cancer Res 2019;8:S87-93. 10.21037/tcr.2018.08.21 - DOI - PMC - PubMed

Publication types